Lee Fairlie to Antibodies, Viral
This is a "connection" page, showing publications Lee Fairlie has written about Antibodies, Viral.
Connection Strength
0,598
-
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. Hum Vaccin Immunother. 2025 Dec; 21(1):2450120.
Score: 0,203
-
High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa. Int J Infect Dis. 2022 Dec; 125:241-249.
Score: 0,174
-
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
Score: 0,050
-
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
Score: 0,045
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
Score: 0,043
-
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 05; 9(5):e309-e322.
Score: 0,042
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0,040